The Centers for Medicare & Medicaid Services is launching a new for state Medicaid programs to purchase prescription drugs at prices aligned with those paid in other countries, known as most-favored-nation pricing. The program, called the GENErating cost Reductions fOr U.S. (GENEROUS) Medicaid Model, will be coordinated by the CMS Innovation Center. CMS said it will issue a request for applications later this fall for drug manufacturers interested in participating in the model. The agency will also seek letters of intent from interested state Medicaid agencies.

Related News Articles

Headline
The White House announced today that it reached agreements with Eli Lilly and Novo Nordisk to align their drug prices with the lowest paid by other developed…
Headline
The AHA and a coalition of organizations yesterday urged House and Senate leaders to pass the Reforming and Enhancing Sustainable Updates to Laboratory Testing…
Headline
The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model…
Headline
The Senate Committee on Health, Education, Labor and Pensions Oct. 23 held a hearing discussing the 340B Drug Pricing Program and its growth and impacts on…
Headline
The Centers for Medicare & Medicaid Services has released an operational guide for Medicare-enrolled providers and suppliers on the Wasteful and…
Headline
A report by the Department of Health and Human Services Office of the Inspector General found that many Medicare Advantage and Medicaid managed care plans…